Drug delivery company Acrux has warned it is at risk of missing its next milestone payment from distributor Eli Lilly because concerns about a potential link between testosterone and heart failure have hampered sales in the United States.
Acrux's lead product is Axiron, a form of testosterone. In January, the US Food and Drug Administration said it would investigate whether testosterone increased the risk of heart attack and stroke in some men. The regulator's move has impacted the industry according to Acrux
"The US testosterone replacement therapy market has been impacted and unless this improves and/or Axiron's share of market increases, the next milestone may not be met in calendar year 2014," the company said. The share price has plunged 63 per cent in the past year, despite Acrux delivering a special dividend at the beginning of the year.
If you or a loved one have suffered a heart attack, stroke, pulmonary embolism or blood clot while taking Axiron or another testosterone medication, call our experienced Axiron attorneys at (888) 606-5297 for a free consultation about your potential Axiron lawsuit.